Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A more widespread adoption of an approach taken by a new scheme in which payment for an anticancer drug is linked to treatment response might create stronger incentives and opportunities for the discovery and application of clinically relevant biomarkers.
Dramatic increases in the prevalence of multidrug-resistant bacteria have put the spotlight on the lack of new antibacterials coming through the pipeline. How might regulatory guidance for clinical trials of antibacterials help tackle this shortfall?
